Published in J Pathol on June 01, 2004
Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet (2010) 3.15
Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res (2011) 2.00
Mist1 Expressing Gastric Stem Cells Maintain the Normal and Neoplastic Gastric Epithelium and Are Supported by a Perivascular Stem Cell Niche. Cancer Cell (2015) 1.90
Nature meets nurture: molecular genetics of gastric cancer. Hum Genet (2009) 1.87
Hereditary diffuse gastric cancer: association with lobular breast cancer. Fam Cancer (2008) 1.45
Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet (2015) 1.36
Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomas. Virchows Arch (2008) 1.15
Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric Cancer (2010) 1.15
Prevention strategies for gastric cancer: a global perspective. Clin Endosc (2014) 1.04
DNA and histone methylation in gastric carcinogenesis. World J Gastroenterol (2013) 1.03
Clinicopathological features of gastric cancer in young patients. Gastric Cancer (2015) 1.02
Why is the hyperplastic polyp a marker for the precancerous condition of the gastric mucosa? Virchows Arch (2005) 1.02
Early gastric cancer: concepts, diagnosis, and management. Int J Clin Oncol (2005) 1.00
Prophylactic laparoscopic-assisted total gastrectomy for hereditary diffuse gastric cancer. JSLS (2007) 1.00
Hereditary diffuse gastric cancer: prophylactic surgical oncology implications. Surg Clin North Am (2008) 1.00
A systematic review of the indications for genetic testing and prophylactic gastrectomy among patients with hereditary diffuse gastric cancer. Gastric Cancer (2011) 0.99
Treatment of resectable gastric cancer. Therap Adv Gastroenterol (2012) 0.99
Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance. Fam Cancer (2012) 0.98
Gastric cancer, Helicobacter pylori infection and other risk factors. World J Gastrointest Oncol (2010) 0.96
p75 neurotrophin receptor suppresses the proliferation of human gastric cancer cells. Neoplasia (2007) 0.94
A short guide to hereditary diffuse gastric cancer. Hered Cancer Clin Pract (2007) 0.93
Clinical management of advanced gastric cancer: the role of new molecular drugs. World J Gastroenterol (2014) 0.92
Role of pathology in the identification of hereditary diffuse gastric cancer: report of a Portuguese family. Virchows Arch (2004) 0.92
A novel proteomics-based clinical diagnostics technology identifies heterogeneity in activated signaling pathways in gastric cancers. PLoS One (2013) 0.90
[Novel pharmaceutical treatment approaches for gastric cancer]. Pathologe (2017) 0.88
Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. PLoS One (2013) 0.88
Oesophageal adenocarcinoma and gastric cancer: should we mind the gap? Nat Rev Cancer (2016) 0.87
Molecular targeted therapies in advanced gastric cancer: does tumor histology matter? Therap Adv Gastroenterol (2013) 0.87
Familial gastric cancer: detection of a hereditary cause helps to understand its etiology. Hered Cancer Clin Pract (2012) 0.86
Hereditary gastric cancer. Pathologe (2012) 0.85
Hereditary diffuse gastric cancer: What the clinician should know. World J Gastrointest Oncol (2015) 0.85
Hereditary diffuse gastric cancer: multidisciplinary case report with review of the literature. Patholog Res Int (2011) 0.84
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? Cancer Biol Ther (2015) 0.83
Immunohistochemical biomarkers in gastric cancer research and management. Int J Surg Oncol (2012) 0.82
Pregnancy after prophylactic total gastrectomy. Fam Cancer (2010) 0.81
Clinical impact of tumour biology in the management of gastroesophageal cancer. Nat Rev Clin Oncol (2016) 0.81
Gastric biomarkers: a global review. World J Surg Oncol (2016) 0.79
Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer. Sci Rep (2014) 0.79
Clinical utility gene card for: Hereditary diffuse gastric cancer (HDGC). Eur J Hum Genet (2013) 0.79
[Hereditary gastric cancer]. Pathologe (2010) 0.78
Early-onset gastric cancer: Learning lessons from the young. World J Gastrointest Oncol (2010) 0.78
Gene methylation profile of gastric cancerous tissue according to tumor site in the stomach. BMC Cancer (2016) 0.76
Mitochondrial DNA alterations in the progression of gastric carcinomas: unexplored issues and future research needs. World J Gastroenterol (2014) 0.75
Molecular alterations in gastric cancer with special reference to the early-onset subtype. World J Gastroenterol (2016) 0.75
Rescue of wild-type E-cadherin expression from nonsense-mutated cancer cells by a suppressor-tRNA. Eur J Hum Genet (2014) 0.75
Report from the 17th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Edmonton, Alberta; 11-12 September 2015. Curr Oncol (2016) 0.75
Clinical Relevance of the Tumor Location-Modified Lauren Classification System of Gastric Cancer. J Gastric Cancer (2015) 0.75
Methylation-silencing RCC1 expression is associated with tumorigenesis and depth of invasion in gastric cancer. Int J Clin Exp Pathol (2015) 0.75
[Hereditary gastric and pancreatic cancer]. Pathologe (2017) 0.75
A case of multiple diffuse gastric carcinoma with regional expression of mutant E-cadherin. Virchows Arch (2008) 0.75
The identification and management of hereditary diffuse gastric cancer in a large Jordanian family. Fam Cancer (2011) 0.75
Signatures of mutational processes in human cancer. Nature (2013) 21.63
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47
International network of cancer genome projects. Nature (2010) 20.35
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08
Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22
ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Consensus statement on the pathology of IgG4-related disease. Mod Pathol (2012) 9.01
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet (2005) 8.45
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature (2013) 7.42
MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol (2007) 6.41
A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet (2008) 6.26
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature (2012) 5.84
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol (2012) 5.70
Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med (2012) 5.69
Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol (2005) 5.63
Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med (2009) 5.63
Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res (2007) 5.62
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol (2010) 5.23
Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. Clin Gastroenterol Hepatol (2006) 4.70
High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol (2007) 4.70
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst (2002) 4.43
Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology (2007) 4.33
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol (2007) 4.33
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell (2003) 4.33
Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nat Genet (2010) 4.20
Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer (2007) 4.06
Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA (2007) 3.62
Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol (2008) 3.49
Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ (2010) 3.44
Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. Nat Genet (2010) 3.37
Idiopathic chronic pancreatitis with periductal lymphoplasmacytic infiltration: clinicopathologic features of 35 cases. Am J Surg Pathol (2003) 3.36
BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene (2003) 3.34
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol (2009) 3.26
Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology (2010) 3.24
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature (2011) 3.22
Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet (2012) 3.19
MicroRNA: implications for cancer. Virchows Arch (2007) 3.17
Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet (2010) 3.15
Sclerosing mesenteritis: clinical features, treatment, and outcome in ninety-two patients. Clin Gastroenterol Hepatol (2007) 3.14
Frequency of TERT promoter mutations in human cancers. Nat Commun (2013) 3.13
p300/CBP and cancer. Oncogene (2004) 3.13
Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer (2007) 3.09
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet (2011) 3.07
Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci U S A (2008) 2.99
Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res (2007) 2.94
Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat Genet (2005) 2.92
Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology (2006) 2.87
Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology (2002) 2.85
The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer (2005) 2.83
Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann Surg Oncol (2007) 2.82
The implications of clonal genome evolution for cancer medicine. N Engl J Med (2013) 2.78
Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology (2002) 2.76
Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. Am J Gastroenterol (2007) 2.73
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72
Chromosome abnormalities in 10 lung cancer cell lines of the NCI-H series analyzed with spectral karyotyping. Cancer Genet Cytogenet (2005) 2.70
Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg (2008) 2.66
Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol (2011) 2.64
Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation. Liver Transpl (2015) 2.63
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biol (2010) 2.60
BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene (2003) 2.56
Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling. Sci Transl Med (2012) 2.55
Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol (2009) 2.55
Sizing up miRNAs as cancer genes. Nat Med (2005) 2.48
Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol (2007) 2.48
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol (2013) 2.48
A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol (2007) 2.47
Multiple common susceptibility variants near BMP pathway loci GREM1, BMP4, and BMP2 explain part of the missing heritability of colorectal cancer. PLoS Genet (2011) 2.47
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer (2008) 2.47
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet (2012) 2.45
The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology (2011) 2.42
AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis (2002) 2.41
A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology (2003) 2.39
Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst (2010) 2.38
Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. Cell Rep (2013) 2.37
Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol (2013) 2.35
Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer. Sci Transl Med (2013) 2.34
Cellular changes in diabetic and idiopathic gastroparesis. Gastroenterology (2011) 2.30
Membranous glomerulonephritis is a manifestation of IgG4-related disease. Kidney Int (2012) 2.28
Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N Engl J Med (2011) 2.25
Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel. Clin Cancer Res (2014) 2.25
The shaping and functional consequences of the microRNA landscape in breast cancer. Nature (2013) 2.22
FOXA1 expression in breast cancer--correlation with luminal subtype A and survival. Clin Cancer Res (2007) 2.22
BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol (2004) 2.21
Phenotypic and functional characterisation of the luminal cell hierarchy of the mammary gland. Breast Cancer Res (2012) 2.18
A consensus prognostic gene expression classifier for ER positive breast cancer. Genome Biol (2006) 2.17
Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res (2004) 2.17